Initial clinical safety results have been promising. In addition BXQ-350 appears to by-pass the blood brain barrier offering hope to patients with brain tumors. A robust clinical development plan is being initiated to maximize the potential of our BXQ-350 platform.
Information about Bexion’s current clinical trials can be found below:
K O M P A S S S T U D Y (closed)
A pharmacoKinetic and safety study of BXQ-350 in cOMPlex Advanced Solid tumors and high-grade gliomaS in adult patients.
Trial can be found at https://www.clinicaltrials.gov/show/NCT02859857
K O U R A G E S T U D Y (currently enrolling)
A Phase 1 pharmacoKinetic and safety Study of BXQ-350 in children and yoUng adults with RelApsed solid tumors, includinG rEcurrent malignant brain tumors.
Trial can be found at https://clinicaltrials.gov/ct2/show/NCT03967093
More information about clinical trials:
In certain circumstances, where patients do not qualify for clinical trials and when no comparable treatment options are available, expanded access may be a viable option.